Background: Hemi-osteoporosis is a common secondary complication of stroke. No systematic reviews of pharmacological and non-pharmacological agents for post-stroke bone health have estimated the magnitude and precision of effect sizes to guide better clinical practice.
Objectives: To examine the benefits and harms of pharmacological and non-pharmacological agents on bone health in post-stroke individuals.